TY - JOUR T1 - Phytochemical Approach Including Total Phenolic and Flavonoid Contents and Evaluation of in vitro ABTS Antioxidant Capacity and Lipoxygenase Inhibition of Anisosciadium lanatum JF - Pharmacognosy Journal Y1 - 2022 A1 - Mohammed Wasel Matar A1 - Shahad Mohammed Nasser Alqahtani A1 - Duaa Adnan Alghafli A1 - Abdullah Abdulhamid Altaweel A1 - Abdullah Jalal Alasoom A1 - Hussein Ali Burshed A1 - Marwan Mohamed Alshawush A1 - Hany Ezzat Khalil KW - ABTS KW - Anisosciadium lanatum KW - Lipoxygenase KW - total flavonoid KW - total phenolic AB -

Anisosciadium lanatum Boiss is commonly known in Bedouins as besbas. Traditional, it is palatable plant and used in medicine of livestock to treat skin conditions . The main objective of current approach was to screen the presence of different kind of metabolites applying standard procedures followed by assessment of total phenolic (TPC) and flavonoids (TFC) contents. In addition, the in vitro ABTS antioxidant and lipoxygenase activities were evaluated. Different organs (leaves, stems and flowers) of Anisosciadium lanatum were extracted using 70% methanol to yield total methanol extracts of leaves (TML), stems (TMS) and flowers (TMF). Results demonstrated that TML, TMS and TMF are characterized by the content of different constituents such as flavonoids, phenolics/tannins, steroids, saponins, and carbohydrates at different levels. Ethyl acetate (EA) and butanol (BT) fractions of TML and TMS demonstrated the highest percentage of TPC and TFC. The results demonstrated the competence of EA and BT as free radical scavenger fractions compared to other fractions and its opportunity to contain bioactive antioxidant metabolites . TML, TMS and TMF exhibited Lipoxygenase inhibitory activity with IC50 values of 4.88, 5.40 and 6.05 μg/mL, respectively when compared to that of the positive control baicalein (IC50: 0.27 μg /mL). In conclusion, present investigation highlighted the potential of Anisosciadium lanatum to be promising candidate with activity against wide range of inflammatory-related diseases.

VL - 14 IS - 6s ER -